Nah. In a situation where fundamentals and balance sheet are very strong but the share structure is preventing uplist, a RS would be the appropriate remedy to unlock the valuation benefits of being on NASDAQ with a $5 share price. Institutions would pile in and make any shorts very sorry.
As I said, it doesn't seem likely but I would be for it if the numbers were right.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links